HexA-Enzyme Coated Polymer Nanoparticles for the Development of a Drug-Delivery System in the Treatment of Sandhoff Lysosomal Storage Disease
Source abstract
Abstract
Lysosomal storage disorders (LSDs) are a set of metabolic diseases caused by mutations in genes that are in charge of the production of lysosomal enzymes, resulting in the buildup of non-degraded substrates and the consequent systemic damage that mainly involves the Central Nervous System (CNS). One of the most widely used and studied treatments is Enzyme Replacement Therapy, which is based on the administration of the recombinant deficient enzyme. This strategy has often proved fallacious due to the enzyme instability in body fluids and its inability to reach adequate levels in the CNS. In this work, we developed a system based on nanotechnology that allows a stable enzyme to be obtained by its covalent immobilization on nanoparticles (NPs) of polylactic acid, subsequently administered to a cellular model of LSDs, i.e., Sandhoff disease, caused by the absence or deficiency of the β-d-N-acetyl-hexosaminidase A (HexA) enzyme. The HexA enzymes, loaded onto the polymeric NPs through an immobilization procedure that has already been investigated and validated, were found to be stable over time, maintain optimal kinetic parameters, be able to permeate the plasma membrane, hydrolyze HexA’s natural substrate, and restore enzyme activity close to the levels of healthy cells. These results thus lay the foundation for testing the HexA-NPs in animal models of the disease and thus obtaining an efficient drug-delivery system.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lysosomal Storage Disorders Research · Calcium signaling and nucleotide metabolism · Cellular transport and secretion
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del Giochetto, 06123 Perugia, Italy
Centro di Eccellenza sui Materiali Innovativi Nanostrutturati (CEMIN), University of Perugia, Via Elce di Sotto 8, 06123 Perugia, Italy
Department of Physics and Geology, University of Perugia, Via Pascoli, 06123 Perugia, Italy
References (57)
Show source-provided references
1. A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay–Sachs disease10.1093/hmg/ddi216 ↗
2. Bicistronic lentiviral vector corrects β-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts10.1016/j.nbd.2005.04.017 ↗
3. Hematopoietic Stem cell transplantation and lentiviral vector-based gene therapy for Krabbe’s disease: Present convictions and future prospects10.1002/jnr.23847 ↗
4. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications10.1016/j.ymthe.2017.03.025 ↗
5. Enzyme replacement therapy for lysosomal storage diseases
6. Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders10.1007/s13346-012-0072-4 ↗
7. Gene Therapy for Fabry Disease: A Review of the Literature10.1007/s40259-013-0032-7 ↗
8. Jurga, S., and Barciszewski, J. (2021). RNA Modifications in Neurodegenerations. Epitranscriptomics, Springer International Publishing. RNA Technologies.10.1007/978-3-030-71612-7 ↗
9. Recombinant Glucocerebrosidase (Imiglucerase) as a Therapy for Gaucher Disease10.2165/11318540-000000000-00000 ↗
10. Vestronidase Alfa: A Review in Mucopolysaccharidosis VII10.1007/s40259-019-00344-7 ↗
11. Cunha, A., Gaubert, A., Latxague, L., and Dehay, B. (2021). PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. Pharmaceutics, 13.10.3390/pharmaceutics13071042 ↗
12. Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., and Emiliani, C. (2019). Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies. J. Funct. Biomater., 10.10.3390/jfb10010004 ↗
13. Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A10.1016/j.jconrel.2017.02.016 ↗
14. CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges10.3389/fmolb.2020.559804 ↗
15. Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease10.1126/sciadv.aax7462 ↗
16. Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs10.3389/fnins.2020.00494 ↗
17. Nanotechnologies for Alzheimer’s disease: Diagnosis, therapy, and safety issues10.1016/j.nano.2011.03.008 ↗
18. Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier10.1007/s40259-018-0309-y ↗
19. Medical Nanotechnology10.2165/00063030-200519040-00001 ↗
20. Wells, C.M., Harris, M., Choi, L., Murali, V.P., Guerra, F.D., and Jennings, J.A. (2019). Stimuli-responsive drug release from smart polymers. J. Funct. Biomater., 10.10.3390/jfb10030034 ↗
21. Drug targeting10.1016/S0928-0987(00)00166-4 ↗
22. Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts10.1166/jnn.2015.9251 ↗
23. Boddu, S.H.S., Bhagav, P., Karla, P.K., Jacob, S., Adatiya, M.D., Dhameliya, T.M., Ranch, K.M., and Tiwari, A.K. (2021). Polyamide/Poly(Amino Acid) Polymers for Drug Delivery. J. Funct. Biomater., 12.10.3390/jfb12040058 ↗
24. Farahani, A., Zarei-Hanzaki, A., Abedi, H.R., Tayebi, L., and Mostafavi, E. (2021). Polylactic Acid Piezo-Biopolymers: Chemistry, Structural Evolution, Fabrication Methods, and Tissue Engineering Applications. J. Funct. Biomater., 12.10.3390/jfb12040071 ↗
25. Hill, M., Cunningham, R.N., Hathout, R.M., Johnston, C., Hardy, J.G., and Migaud, M.E. (2019). Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT. J. Funct. Biomater., 10.10.3390/jfb10020026 ↗
26. pH-tunable nanoparticles composed of copolymers of lactide and allyl-glycidyl ether with various functionalities for the efficient delivery of anti-cancer drugs10.1016/j.colsurfb.2021.111801 ↗
27. Block copolymers in Alzheimer’s disease therapy: A perceptive to revolutionize biomaterials10.1016/j.jconrel.2021.11.007 ↗
28. Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems10.1016/j.cej.2018.01.010 ↗
29. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters10.1016/j.ejpb.2007.08.001 ↗
30. A review on nanotechnology: Properties, applications, and mechanistic insights of cellular uptake mechanisms10.1016/j.molliq.2021.118008 ↗
31. Single enzyme nanoparticle, an effective tool for enzyme replacement therapy10.1007/s12272-020-01216-3 ↗
32. Rigon, L., Salvalaio, M., Pederzoli, F., Legnini, E., Duskey, J.T., D’Avanzo, F., De Filippis, C., Ruozi, B., Marin, O., and Vandelli, M.A. (2019). Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles. Int. J. Mol. Sci., 20.10.3390/ijms20082014 ↗
33. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier10.1080/17425247.2020.1698544 ↗
34. Duskey, J.T., Da Ros, F., Ottonelli, I., Zambelli, B., Vandelli, M.A., Tosi, G., and Ruozi, B. (2020). Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function. Molecules, 25.10.3390/molecules25204593 ↗
35. Calzoni, E., Cesaretti, A., Montegiove, N., Di Michele, A., and Emiliani, C. (2021). Enhanced Stability of Long-Living Immobilized Recombinant β-d-N-Acetyl-Hexosaminidase A on Polylactic Acid (PLA) Films for Potential Biomedical Applications. J. Funct. Biomater., 12.10.3390/jfb12020032 ↗
36. Enzyme immobilization onto the nanomaterials: Application in enzyme stability and prodrug-activated cancer therapy10.1016/j.ijbiomac.2019.12.064 ↗
37. Gangliosides and Gangliosidoses: Principles of Molecular and Metabolic Pathogenesis10.1523/JNEUROSCI.0822-13.2013 ↗
38. Lysosomal storage diseases
39. Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs10.1016/0024-3205(68)90024-6 ↗
40. An enzyme with properties similar to those of β-N-acetylhexosaminidase S is expressed in the promyelocytic cell line HL-6010.1042/bj2670111 ↗
41. Crystallographic Structure of Human β-Hexosaminidase A: Interpretation of Tay-Sachs Mutations and Loss of GM2 Ganglioside Hydrolysis10.1016/j.jmb.2006.04.004 ↗
42. New Approaches to Tay-Sachs Disease Therapy10.3389/fphys.2018.01663 ↗
43. New therapeutic options for lysosomal storage disorders: Enzyme replacement, small molecules and gene therapy
44. Lysosomal storage diseases: Current therapies and future alternatives
45. Calzoni, E., Cesaretti, A., Tacchi, S., Caponi, S., Pellegrino, R.M., Luzi, F., Cottone, F., Fioretto, D., Emiliani, C., and Di Michele, A. (2021). Covalent Immobilization of Proteases on Polylactic Acid for Proteins Hydrolysis and Waste Biomass Protein Content Valorization. Catalysts, 11.10.3390/catal11020167 ↗
46. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding10.1016/0003-2697(76)90527-3 ↗
47. Intermediate forms of human β-N-acetylhexosaminidase lack activity towards 4-methylumbelliferyl β-N-acetylglucosaminide 6-sulphate10.1042/bj2440801 ↗
48. Occurrence of an Anomalous Endocytic Compartment in Fibroblast from Sandhoff Disease Patients10.1007/s11010-009-0277-0 ↗
49. Molecular analysis of theHEXAgene in Italian patients with infantile and late Onset Tay-Sachs disease: Detection of fourteen novel alleles10.1002/humu.9363 ↗
50. Molecular and functional analysis of the HEXB gene in Italian patients affected with Sandhoff disease: Identification of six novel alleles10.1007/s10048-008-0145-1 ↗
51. Morena, F., Argentati, C., Calzoni, E., Cordellini, M., Emiliani, C., D’Angelo, F.A., and Martino, S. (2016). Ex-Vivo tissues engineering modeling for reconstructive surgery using human adult adipose stem cells and polymeric nanostructured matrix. Nanomaterials, 6.10.3390/nano6040057 ↗
52. Koelmel, J.P., Li, X., Stow, S.M., Sartain, M.J., Murali, A., Kemperman, R., Tsugawa, H., Takahashi, M., Vasiliou, V., and Bowden, J.A. (2020). Lipid Annotator: Towards Accurate Annotation in Non-Targeted Liquid Chromatography High-Resolution Tandem Mass Spectrometry (LC-HRMS/MS) Lipidomics Using a Rapid and User-Friendly Software. Metabolites, 10.10.3390/metabo10030101 ↗
53. LC/MS lipid profiling from human serum: A new method for global lipid extraction10.1007/s00216-014-8255-0 ↗
54. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications10.1016/j.addr.2012.01.020 ↗
55. Smart polymers for the controlled delivery of drugs—A concise overview10.1016/j.apsb.2014.02.005 ↗
56. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging10.1016/j.nano.2011.05.016 ↗
57. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies10.1021/acs.chemrev.5b00589 ↗